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Abstract
Ophthalmic gene therapy is an intellectual and intentional manipulation of desired gene expression 
into the specific cells of an eye for the treatment of ophthalmic (ocular) genetic dystrophies and 
pathological conditions. Exogenous nucleic acids such as DNA, small interfering RNA (siRNA), 
micro RNA (miRNA), etc., are used for the purpose of managing expression of the desired 
therapeutic proteins in ocular tissues. The delivery of unprotected nucleic acids into the cells is 
limited due to exogenous and endogenous degradation modalities. Nanotechnology, a promising 
and sophisticated cutting edge tool, works as a protective shelter for these therapeutic nucleic 
acids. They are able to be safely delivered to the required cells in order to modulate anticipated 
protein expression. To this end, nanotechnology is seen as a potential and promising strategy in 
the field of ocular gene delivery. This review focused on current nanotechnology modalities and 
other promising non-viral strategies being used to deliver therapeutic genes in order to treat 
various devastating ocular diseases.
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1. Introduction
Over the last few decades, gene based therapeutic clinical strategies have been extensively 
explored for the treatment of ocular diseases1–8. Gene therapy, from its inception, aims to 
repair or replace the disease-causing mutations by delivering the suitable therapeutic genetic 
materials along with the rational regulatory elements into the desired cells to express the 
deficient protein at normal levels. For therapeutic purposes, it has already been established 
that the genomic and the coding and/or non-coding RNA sequences can be modulated by 
introducing nucleic acids into the ocular tissues (Fig. 1). The effectiveness of inserting 
therapeutic genes into the desired cell is not only manipulated by DNA designing strategies, 
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but also significantly depends on the efficiency and safety of its delivery vehicle(s). This 
review will summarize details on several ocular dystrophies of the leading causes of 
blindness in the world. In addition, major focus will be on the existing preclinical studies on 
nanotechnology-motivated synthetic non-viral gene delivery vehicles. These vehicles have 
already resulted in the improvements of structural and functional recovery of several major 
retinal disorders in animal models, and might have promising clinical significance in future 
human ocular gene therapy.
2. Ocular disorders
2.1. Retinitis pigmentosa
Retinitis pigmentosa (RP) is a group of clinically and genetically heterogeneous 
disorders3, 9. RP has a worldwide prevalence of 1 in 3000 to 7000 people10. This is 
characterized by initial night blindness (tunnel vision) due to the loss of rod cells in the 
periphery of the retina. As the disease progresses, cone cells start to degenerate, which leads 
to complete physical blindness of the patient via loss of central vision. The reason behind 
the loss of cone cells in RP cases is not yet clear, although rod cells possess defective genes. 
In this context, it is assumed that these cone cell dystrophies might be due to loss of rod cell-
based supporting factors11. Multiple genetic inheritance patterns were found in RP patients. 
Among these patients, 15–25% of cases were autosomal dominant (adRP), 5–25% of cases 
showed autosomal recessive (arRP), and 5–15% showed X-linked traits10, 12. In general, RP 
is divided into two categories: one is syndromic (40%), and the other one is non-syndromic 
(or simple, 60%). The non-syndromic, or simple RP, is limited to the eye. The syndromic 
RP is beyond the eye, which also affects other organs and tissues in the body. The most 
frequent and studied syndromic disease is Usher syndrome (hearing loss followed by RP)10.
2.1.1. Rhodopsin (Rho) mutations—RP is associated with more than 100 mutations12 
in the different regions of the rhodopsin (Rho) gene that accounts for 30–40% of adRP10, 
and thus is genetically heterogeneous3, 5, 10. Rhodopsin protein helps to keep the structural 
integrity of the rod outer segments, as it was observed that Rho−/− mice were not able to 
extend rod outer segments. Rhodopsin protein is covalently associated with the 11-cis retinal 
chromophore to form a visual pigment, G protein-coupled receptor (GPCR), and plays a 
vital role in the conversion of electromagnetic radiation (light) to electrical signal in the 
retina, which is further processed in the brain as an image10. Upon absorption of a photon, 
the chromophore (11-cis retinal) is isomerized to all-trans (Fig. 2a) and causes 
conformational changes in the visual pigment (GPCR), which triggers a signal transduction 
cascade. This cascade results in the closure of nonselective cyclic guanosine 3'-5'-
monophosphate (cGMP)-gated cation channels in the photoreceptor (PR) outer segment and 
hyperpolarization of the PR plasma membrane that generates receptor potential at PR 
synapse. Rod cells are responsible for night vision and remain sensitive as they are activated 
by single photons.
Mutation in the Rho gene can affect the rod cell functions at different severity levels. The 
same RP phenotype is observed from mutations in different regions of the rhodopsin gene 
that can cause different amino acid substitutions, and therefore leads to different rates of 
progression of this disorder. When the interdiscal protein mutates, it remains less severe than 
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that in the cytoplasmic or retinal binding site domains. Mutated rhodopsin protein in the 
cytoplasm possesses inappropriate transport properties towards the outer segment of rod 
cells.
The adRP currently does not have any therapeutic support. Rho mutations are classified as 
Class I and Class II based on tissue culture studies13–15. In Class I mutation, opsin expresses 
wild type level and binds to 11-cis retinal to form retinal photopigment (Fig. 2a) along with 
proper folding.
Class II mutation is the major cause of RP in North America15. Class II mutants accumulate 
and remain misfolded in the endoplasmic reticulum (ER). The misfolded protein causes 
activation of unfolded protein response (UPR), and leads to the cellular dystrophies 
associated with various ocular diseases. The first identified, and so far the most important 
Class II, RP is associated with the single missense mutation in the codon 23 in the human 
opsin gene. This mutation results in one proline substitution by histidine (RhoP23H), and is 
responsible for the most frequent cause of adRP15. The cause related to the RhoP23H 
toxicity remains unclear. Due to the dominant nature of the disorder, suppression and 
replacement of the gene are considered a useful and logical therapeutic approach in the 
treatment of the mutational heterogeneity of these adRP cases.
2.1.2. Phosphodiesterase 6b (PDE6b)—Rod cyclic guanosine 3'-5'-monophosphate 
(cGMP)-specific phosphodiesterase-6 (PDE6) enzyme is responsible for the hydrolysis of 
cytoplasmic cGMP in photoreceptor cells of the retina. PDE6 is a peripheral membrane 
heterotetramer enzyme that is composed of two inhibitory gamma (γ) subunits and two 
catalytic homologous α and β subunits in rods (PDE6αβγγ), and related α’ subunits in cones 
(PDE6 α’α’γγ). PDE6 plays a key role in the photo-transduction cascade by regulating 
cGMP levels in the photoreceptor cells. Guanylate cyclase synthesizes cGMP from GTP and 
regulates the ion channel in the plasma membrane. During dark adaptation, cGMP keeps the 
ion channels open, thus allowing the influx of calcium ions into the outer segment of 
photoreceptors that causes overall depolarization of these cells. In light adaptation, PDE6 
hydrolyses the cGMP and thus the cGMP amount is reduced, which leads to closing of 
cGMP gated ion channels and overall hyperpolarization of the photoreceptor cells. The beta 
subunits of PDE6 are encoded by the PDE6B gene, and therefore mutations in this PDE6B 
gene lead to malfunctioning of the PDE6 enzyme activity. In the light and dark adapted 
mechanism, the non-functional PDE6 enzyme is not able to hydrolyse cGMP, which results 
in accumulation of cGMP without closing the ion channels. This leads to the accumulation 
of excess calcium in cytoplasm that finally induces the degeneration of photoreceptor cells, 
resulting in blindness16. The mutation in the PDE6B gene is responsible for the arRP in 
humans. This earliest and most severe form of the disease is contributing to 5% of all arRP 
cases.
2.2. Usher syndrome
Usher syndrome (USH) is a genetically heterogeneous group of autosomal recessive genes 
that affects both hearing and vision (related to inner ear and retina, the most sensitive 
neurosensory organs in mammals), along with occasional loss of balance. This syndrome 
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was first discovered by Scottish ophthalmologist Charles Usher in 1914, upon examination 
of over 69 patients who were dealing with deafness with RP. There is a predictable 
occurrence in which 3–6 per 100,000 human patients are observed with both blindness and 
deafness17, 18. Clinically, there are three types of Usher syndrome (USH1, USH2 and 
USH3)3, 19, 20. Regarding the onset of hearing loss, USH1 is the most severe19. In USH1, a 
child is born with severe to profound deafness. The vision problem starts within 10 years of 
age, and progresses quickly to complete blindness. The child with USH1 might also have 
more balance problems associated with sitting and walking than normal. USH2 is 
comparatively less severe than USH1. The child is born with moderate to severe hearing loss 
and normal balance. Night vision problems appear in late childhood or teens with slow 
progressive loss of vision19. In USH3 cases, the child is born with normal hearing and 
balance, but there is an advanced loss of hearing by adolescence19. Vision loss varies in 
severity, and night vision problems develop during the teenage years. Night blindness and 
loss of peripheral vision are the early symptoms of RP due to the loss of rod photoreceptor 
cells. As the disease progresses, the cone photoreceptor cells also start to degenerate, leading 
to loss in the central vision that finally results in blindness of USH patients.
Significant amounts of research are currently underway to identify the genes related to USH 
syndrome. There are six genes that have been found so far to be associated with USH1, and 
these are MYO7A (myosin VIIA), USH1C (harmonin), CDH23 (cadherin 23), PCDH15 
(protocadherin 15), SANS (scaffold protein containing ankyrin repeats and sam domain) and 
CIB2 (calcium- and integrin-binding protein 2) 18. The proteins, encoded by these genes, are 
expressed in the cochlear hair cells in the inner ear, as well as in the photoreceptor cells of 
the retina. These USH proteins are helping the inner ear hair cell bundles in their 
development and maintenance of their function and stability. Mutations in these genes can 
result in the loss of protein functions that finally lead to the prevention of hair cell 
developments and loss in hearing. In mice, MYO7A has also been found in the RPE (retinal 
pigmented epithelium) cells, along with different sections of photoreceptor cells like 
connecting cilia, inner segment, and synapse. The USH2 (usherin, VLGR1 and whirlin) and 
USH3 (clarin-1) proteins are also found in the same sections of photoreceptor cells in the 
mouse retina. Literature shows that MYO7A functions the same way in both human and 
mouse RPE cells with respect to melanosome mortality21.
2.3. Stargardt’s disease
Stargardt’s is an autosomal recessive juvenile disorder22 which mainly occurs in children 
between the ages of 6–16 years, with a prevalence of 1 in 8000 to 10000 patients23. This 
common genetic macular disorder presents throughout the world, due to the mutation in a 
gene that encodes a photoreceptor ATP binding cassette (ABC) lipid transporter protein 
(more commonly known as ABCA4)1, 24, 25. ABCA4 is mainly expressed in photoreceptor 
cells and remains in the outer segment disc membrane25. In dark adaptation, opsin protein 
remains covalently conjugated with the 11-cis retinal chromophore. During light activation, 
this 11-cis retinal is isomerized to the all-trans retinal (atRAL) form that isomerizes back to 
11-cis retinal in RPE cells to reconstitute the photopigment in maintaining the visual cycle 
(Fig. 2b). In this process, atRAL is converted to all-trans retinol (atROL) by all-trans retinol 
dehydrogenase 8 (atRDH8), and is transported to the RPE cells by interphotoreceptor 
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retinoid-binding proteins (IRBP). Through some enzymatic pathways, atROL is now 
converted back to 11-cis retinal in RPE, and is immediately shuttled back to the 
photoreceptor outer segment by IRBP to reconstitute rhodopsin photopigment. During this 
process, there is another pathway where a fraction of atRAL is conjugated with 
phosphatidylethanolamine (PE) to form N-retinylidenephosphatidylethanolamine (N-ret-PE) 
in the disc membrane lumen side24. The flipase ABCA4 protein binds with N-ret-PE and 
flips it from the lumen side to the cytoplasmic side of the disc membrane using ATP energy 
source24. Once this N-ret-PE is brought to the cytoplasmic side, it is hydrolysed by all-trans 
retinol dehydrogenase 8 (RDH8) to atROL and PE. Therefore, ABCA4 makes sure the disc 
membrane atRAL is converted to atROL in cytoplasm, and is shuttled towards RPE to 
regenerate 11-cis retinal.
Mutation in the ABCA4 gene can cause the accumulation of N-ret-PE in the lumen side of 
the disc membrane, which facilitates further possible reaction with another molecule of 
atRAL in the disc membrane to form a phosphatidyl pyridinium diretinoid derivative A2PE 
(2: 1 ratio)25. Under normal phagocytocis of photoreceptor cells, A2PE is engulfed by RPE 
and degraded to A2E by lysomal enzymes. RPE cells are not able to metabolize the A2E that 
leads to a high amount of A2E accumulation as fluorescent lipofusin25. This A2E 
accumulation causes excessive generation of reactive oxygen species (ROS) and leads to 
degeneration of RPE cells. The macula also has a high density of photoreceptor cells, and 
therefore causes high levels of A2E accumulation. RPE, just underlying the macula (which 
possesses the highest density of cone photoreceptor cells), plays a key role in providing the 
structural and functional integrity of photoreceptor cells. The loss of RPE cells causes 
damage to the photoreceptor cells in the macula, which finally leads to Stargardt’s disease.
2.4. Leber congenital amaurosis (LCA)
Leber congenital amaurosis (LCA) is an autosomal recessive inheritance pattern which was 
found by Theodor Leber in 1869. So far, there are 14 genes evaluated which are responsible 
for this severe congenital blindness that presents in early childhood26. The worldwide 
prevalence of this disease is 1 out of 30,000 cases 27, 20% of all congenital blindness, and 
5% of all inherited retinal dystrophies. One of the most important mutations is the RPE65 
gene that encodes RPE65 (RPE-specific 65 KDa) protein in RPE cells 6, 8, 28, 29. This 
protein works as a retinoid isomerohydrolase in RPE cells to convert all-trans retinoid to 11-
cis retinal in the reconstruction process of photopigments in the photoreceptor cells, which 
completes the visual cycle6 (Fig. 2b). Therefore, mutation in the RPE65 gene can cause a 
generation of non-functional RPE65 protein that will not be able to regenerate 11-cis retinal, 
and causes genetically heterogeneous and severe visual impairment at birth or during the 
first month of life. The RPE65 thus causes the disturbances in the visual cycle at this early 
stage of life.
Another form of severe LCA gene is the retina specific guanylate cyclase-1 (GUCY2D), 
which encodes guanylate cyclase-1 (GC-1) in the photoreceptor cells that convert GTP to 
cGMP and control the cyclic nucleotide-gated (CNG) ion channels in the photoreceptor cell 
plasma membrane28, 30. Therefore, GC-1 plays a vital role in the visual photo-transduction 
process and conversion of electromagnetic radiation to chemical signals. The mutation in 
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this gene causes malfunctioning of GC-1 protein, which impairs the production of cGMP 
that leads to a permanent closure of the cGMP gated channel.
Proto-oncogene tyrosine-protein kinase (MER)31 is a transmembrane protein that is encoded 
by the MERTK gene in humans. This protein has an intracellular tyrosine kinase domain. 
The extracellular signaling domain of this protein remains on the apical portion of RPE 
cells32. MERTK signaling plays an important role in the daily clearance of shed 
photoreceptor outer segment debris by RPE phagocytosis and survival of photoreceptor cells 
of the retina32. Therefore, it helps to inhibit the intracellular antigen-induced inflammation 
and autoimmune responses. It is observed that 0.6% of LCA is caused by the mutation of 
this MERTK gene, which encodes non-functional MER protein. Mutation in this gene 
causes the reduction of phagocytic activity of RPE cells that results in the accumulation of 
photoreceptors shed in the subretinal space of the retina. As a consequence, the subretinal 
debris generates inflammation and autoimmune diseases and blocks the oxygen and nutrition 
supply to photoreceptor cells. These detrimental effects lead to rapid loss of vision due to 
photoreceptor degenerations.
2.5. Choroideremia
Choroideremia (CHM), an X-linked inheritance, was found in 1871 by Mauthner, and is the 
leading rare inheritance with a prevalence of 1 in 50,000 patients33. This disease causes a 
progressive degeneration of the choroid, retinal pigment epithelium, and retina that leads to 
loss of peripheral vision (night blindness) followed by loss of central vision in middle age. 
Female carriers have a rare progression of degeneration, but the males are affected by severe 
damage of RPE cells and choriocapillaries that develop night blindness during adolescence 
and complete loss of visual acuity by late adulthood. Choroideremia is caused by a mutation 
in the CHM gene that encodes ubiquitously expressed Rab-escort protein-1 (REP-1)33. 
REP-1 plays a key role in intracellular trafficking of vesicles to the cellular compartments. 
The mutation in the CHM gene remains null most of the time, and absence of this protein 
results in the severe effect of trafficking of the opsin protein to photoreceptor outer segment, 
migration of melanosome to the apical part of RPE cells, and phagocytosis activity of RPE 
cells.
2.6. Diabetic retinopathy (DR)
There are 93 million people suffering from diabetic retinopathy (DR) worldwide34. Diabetes 
can cause damage to the retinal blood vessels that feed the retina. The leaky blood and other 
fluids can cause thickening and swelling of the retina35. Fluid is accumulated by chronic 
high blood sugar levels, which cause blurred vision. Hyperglycemia is assumed to be the 
main reason for microvascular complications in DR, where generation of reactive oxygen 
species, vascular growth factor, and increase in vascular permeability play a vital role. 
Retinal vasculature plays a supporting role in the health of retinal neuronal and glial cells, 
and they are degenerated as the microvascular complications begin. DR can sometimes be 
controlled if the blood glucose level is stabilized, but not in all cases. For example, DR 
associated with gene alteration may not always be controlled by the long-term management 
of blood sugar by using insulin therapy. Currently, multidisciplinary strategies are being 
evaluated, such as laser photocoagulation, anti-vascular endothelial growth factor (anti-
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VEGF), and intravitreal steroid therapies. With the progression of DR, proliferative DR 
generates as the retinal blood vessels proliferate towards the retinal cells and vitreous. This 
leads to the generation of new blood vessels and results in vitreous hemorrhage, retinal 
detachments, and increase in the permeability of retinal blood vessels.
2.7. Age-related macular degeneration (AMD)
Symptoms of age-related macular degeneration generally present around age 60, and are 
caused by damage to the macula, according to a National Eye Institute (NEI, USA) report 15 
million Americans and millions of people around the world are affected by this devastating 
retinal disorder. Macular degeneration does not affect the majority of patients until old age, 
and it is therefore difficult to study the sequential pattern in family members. There are two 
forms of AMD; one is “DRY” (non-nonvascular) and the other is “WET” (neovascular) 
AMD. The majority of AMD presents in dry form. Dry AMD is associated with the 
deposition of yellowish lipid proteins known as drusen under the retina that develop slowly 
and lead to gradual loss in central vision. Dry AMD can progress to geographic atrophy or 
the more devastating wet form. In wet AMD, an abnormal angiogenesis quickly leads to the 
choroidal neovascularization (CNV) within the retina and degenerates photoreceptor cells in 
the macula. This is responsible for 90% of AMD related blindness. There are some 
treatments available for wet AMD that involve inhibiting the growth of new blood vessels. 
Several delivery approaches of anti-angiogenic drugs like bevacizumab (trade name: 
Avastin) or ranibizumab (trade name: Lucentis) have been studied to inhibit vascular 
endothelial growth factor A (VEGF-A), which is responsible for the proliferation and 
growth of new blood vessels 36. There is no specific gene candidate established for AMD, 
and thus gene therapy remains an unpredictable therapeutic approach so far.
2.8. Glaucoma
Glaucoma is the second leading cause of blindness in the world. Overall, 9% to 12% of 
blindness is attributed to glaucoma. Damage to the optic nerve causes irreversible dystrophy 
in the eye, leading to blindness37. Increased intraocular pressure (IOP) is a key risk factor 
associated with this disease. However, this is not a guaranteed cause of glaucoma, as it is 
observed that 25% of glaucoma patients do not have elevation in their IOP37. In the anterior 
chamber, the aqueous humor forms by the ciliary body and is removed by the trabecular 
meshwork outflow pathways. IOP is based on the rate of removal of this aqueous humor 
from the interior chamber, which under normal conditions remains balanced with the rate of 
formation. The loss of retinal ganglion cells (RGCs) leads to damage in the ganglion cell 
axons, which finally degenerates the optic nerve. There are several therapeutic approaches 
developed so far to reduce the IOP by using drugs or surgery. The neuroprotection of these 
RGC cells is established as another well-studied therapeutic approach using different 
neuroprotective agents.
3. Ocular gene delivery
The success of retinal gene therapy primarily depends on the efficiency of the delivery 
vehicle to the targeted cells. The monogenic nature of retinal diseases is the basis for using 
the gene replacement therapeutic strategies. Two main approaches have been shown to be 
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promising for the delivery of therapeutic genes to the targeted cells. One approach is viral 
vector, and the other is a non-viral synthetic cargo-based gene delivery vehicle.
The targeting and delivery efficiency of the viral vectors depends on the vector serotype and 
nature of targeting tissues. Different types of viral vectors, including adenovirus, adeno-
associated virus (AAV, a non-pathogenic), and lentivirus, were demonstrated to be efficient 
for the retinal tissues in in vivo animal models and in vitro tissue cultures. To date, viral 
vectors are among the most commonly used vectors for gene therapy. Among these, AAVs 
(Fig. 3) are currently the most frequently used viral vectors and AAV2 is the most widely 
used AAV serotype38. Significant progress has been made using viral vector for gene 
targeting. For example, in 2001, the successful viral gene replacement therapy using AAV 
was carried out in three Briard dogs with RPE65 mutation39. Delivery of the MYO7A gene 
(~9kb), packaged in AAV2 and AAV5, was injected into the subretinal space of the shaker 1 
mice of a USH1 model40. By splitting into two separate AAV virions that contained splice 
donor and splice acceptor independently, they were able to efficiently express large MYO7A 
cDNA (~6.7 kb) in vitro and in vivo 40. The use of EIVA (equine infectious anemia virus) 
lentivirals mediated delivery of large wild type ABCR genes (~6.8kb) into the subretinal 
space of ABCR−/− mice, which increased the transduction efficiency of both rod and cone 
photoreceptor cells and decreased the toxic A2E levels in RPE cells41, 42, etc. However, the 
packaging capacities of AAV and lentivirus vectors are limited to ~5 and 9 kb, respectively. 
This size capacity restricts their delivery efficiency for large therapeutic genes. Therefore, 
this can also limit the delivery of large genes which might be composed of non-coding 
elements (e.g. intron) required for the improvement of in vivo gene expression43. In 
addition, the major drawbacks are their potential immunogenicity, carcinogenesis, broad 
tissue tropism, and genomic insertional mutagenesis that generate severe patient outcomes.
Based on these disadvantages of viral vectors, synthetic non-viral gene delivery and 
replacement methods have been evaluated as promising gene delivery alternatives. This 
synthetic field has several important advantages, which include nonimmunogenecity, ease 
and low production costs, simplicity in manipulating molecular structure according to 
requirements, and most importantly, safety to the genome. Therefore, this area of research 
has been growing as an attractive and opportunistic field for the development of promising 
synthetic lipid based liposomes, polymers (linear and branched dendrimers and 
polysaccharides), and polypeptide based gene carriers. Next, we will review recent progress 
for using non-viral nanoparticles (NPs) to carry out gene targeting in ocular cells.
3.1 Lipid based liposomes vehicles
Lipid based liposomes are widely applied as non-viral gene delivery vectors. It was first 
discovered in the 1980s when phosphatidylserine phospholipid was utilized to compact and 
deliver SV40 DNA to the monkey kidney cells44. The constituent lipid molecules are 
composed of a cationic or neutral or zwitterionic head group, a hydrophobic tail group, and a 
linker group in between them. When these lipid molecules come into contact with negatively 
charged DNA, they form a complex (lipoplex, schematically presented in Fig. 5a) with the 
dimension of 100–300 nm. The shape and overall charge of the complex depends on the 
structure of the lipid and conditional adjustments. The overall charge of the lipoplex remains 
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positive, which helps it to interact with the cell surface, followed by the fusion with cell 
membrane and internalization into the endosomal compartment45. To enhance the NP 
stability and transfection efficiency, a neutral/zwitterionic lipid such as fusogenic 
phospholipid DOPE (1, 2-dioleoyl-3-phosphatidylethanolamine) or membrane component 
cholesterol are introduced in the lipoplex formulation (Fig. 4a). DNA gets released into the 
cytosol generally via an endosomal escape pathway.
For the first time in 1996, the beta galactosidase reporter gene, under the control of 
cytomegalovirus (CMV) promoter, was administered in the adult Wistar rats using three 
cationic liposomes via topical, anterior chamber, vitreous, and subretinal space routes46. The 
three liposomes were TMAG (N-(triethylamminoacetyl)-didodecyl-D-gluamate), DDAB 
(dimethyldioctadecylammonium bromide), and DC-Cholesterol (3-beta [N-(N’-N’-
dimethylaminoethane)-carbamyl] cholesterol) (Fig. 4a). The gene was expressed in the 
RGCs on topical administration using TMAG and DC-cholesterol, but not by using DDAB 
up to 1 month. The TMAG liposome directed delivery of the gene and exhibited its highest 
level of expression among all three liposomes, irrespective of administrative route. The 
major problem associated with this technique was that the expression pattern was seen only 
in RGCs and RPE cells, whereas no expression was found in photoreceptor cells.
In 2005, Kachi and colleagues showed that the LacZ gene under the control of vitelliform 
macular dystrophy 2 (VMD2) promoter transduced to the RPE cells by using commercial 
40% lipofectamine 2000 (Lf)47. Use of another lipid carrier, NeuroPorter, was tolerated 
well47. At two weeks, the scotopic a- and b- wave electroretinography (ERG) values were 
reduced by 40% and 8%, respectively, after subretinal injection of Lf in adult bulb/c mice. 
On the other hand, after 10% of NeuroPorter injection in the subretinal space, normal retinal 
morphology and functions were revealed for up to 14 days, and expressed in the RPE cells 
without any noticeable toxicity to retinal cells. Due to phagocytic activity of RPE cells, the 
transfer of reporter or therapeutic genes using lipid complex (lipoplex) is feasible (Fig. 5a), 
and may be a future therapeutic approach for RPE cell-related human ocular diseases.
More recently in 2014, Puras and colleague showed that a novel noisome composed of 
cationic lipid 2, 3-di (tetradecyloxy) propan-1-amine with polysorbate 80 additive, could 
deliver pCMS-EGFP plasmid DNA into the rat retina48. Injection into the subretinal space 
transduced both photoreceptor and RPE cells. Intravitreal injection expressed a uniform 
distribution of the reporter EGFP gene throughout the inner retina. Also in 2014, a novel 
strategy was discovered when liposome-proteamine decorated with cell-penetrating nuclear 
localizing signal peptides entrapped functional DNA and expression in the RPE cells49. So 
far, all of these ocular gene therapeutic approaches are limited to proof-of-principle steps 
and in the near future we can expect more novel lipid based formulations for human use.
3.2 Polymer based vehicles
A cationic polymer combines with negatively charged anionic DNA and forms a polyplex 
(Fig. 4b) of different surface charges45. The well-known polymers used for ocular gene 
delivery are composed of biopolymers (proteins), dendrimers, polysaccharides, polylysin, 
polyethyleneimines and small organic biocompatible lactic acid (e.g. PLA) and/or glutamic 
acid (e.g. poly (lactic-co-glycolic acid) molecules (Fig. 4b). In 2013, Puras and colleagues 
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evaluated the gene delivery efficiency of low molecular weight oligochitosan (Fig. 4b) and 
pCMS-EGFP polyplex in vitro and in vivo50. This polyplex protected plasmid DNA from 
nuclease degradation and transfected well to the ARPE 19 cells at pH 7.1. Subretinal 
injection expressed EGFP to the RPE cells, while intravitreal injections exhibited 
transfection to the inner nuclear layer, plexiform layer, and primarily to RGCs in rat retina.
In 2014, Mitra and colleagues synthesized and characterized an ethylene glycol modified 
chitosan (glycol chitosan, GCS, Fig. 4b) and pCBA-EGFP polyplex that protected plasmid 
DNA from nuclease, which expressed reporter EGFP gene in the RPE cells when injected 
into the subretinal space of adult Balb/c mice without affecting the morphology and function 
(using ERG) of retinal cells51. In 2012, Klausner and colleagues evaluated the enhancement 
of transgene expression using chitosan DNA nanoformulation on topical administration on 
the rat cornea52. At 1 day post injection of chitosan DNA complex, it was observed that 
expression of CpG free pCpG-Luc plasmid DNA enhanced by 7.1, 116.8, and 76.8 folds, 
compared to commercially available gWiz-CMV-Luc, pPEI-CMV, and pPEI-UbC plasmid 
DNAs respectively, and demonstrated the development of effective vectors for corneal gene 
therapy52. Another biopolymer gelatin has also been investigated to deliver and significantly 
express mucin MUC5AC (responsible for dry eye syndrome) transgene into the cornea and 
conjunctiva in vivo53. In 2012, Delgado and colleagues reported the ocular gene therapy 
using solid lipid NPs (SLN) composed of biocompatible dextran, protamine, and a plasmid 
DNA (pCMS-EGFP or pCEP4-RS1)54. Dextran is a neutral nonionic polysaccharide and 
combines with cationic polymer to entrap, stabilize, and protect negatively charged DNA. 
On topical administration of SLN to the rat eye, reporter EGFP gene was expressed in the 
cornea and provided a strategic opportunity to deal with various ocular surface diseases54.
In 2014, Alqawlaq and colleagues demonstrated the localization of Cy5 labelled pCMV-
GFP plasmid DNA into the nerve fiber layer of the retina by intravitreal administration 
using Gemini surfactant, whereas the same happened to anterior chamber tissues including 
limbus, iris, and conjunctiva on topical administration to the 4 week old C57BL/6 mice55. 
Intravitreal route of injection is promising, as this reduces the induction of photoreceptor 
cell degeneration seen during subretinal injections. However, this route possesses huge 
viscosity, and thus provides resistance to the mobility of cationic polyplexes (Fig. 4b). 
Therefore, when the polyplexes are strategically coated with the hyaluronic acid (HA, 
component of vitreous matrix), they are less aggregated and able to flow more easily 
through the vitreous space. Most recently in 2015, Martens and colleagues have 
demonstrated that in an ex vivo experiment where cationic N, N′-cystaminebisacrylamide-4-
aminobutanol (p (CBA-ABOL) vector was coated with the HA, there was a significant 
amount of enhancement in the gene expression in the retina via intravitreal route of 
administration 56.
Albumin, a widely used protein carrier, is retained with a high percentage (60–70%) among 
all the proteins in the vitreous compartment 57. Therefore, this biocompatible and 
biodegradable component is safe to use for in vivo ocular gene therapy. In 2007, Mo and 
colleagues found enhanced Cu, Zn superoxide dismutase (SOD1) gene expression by 5 fold, 
compared to the untreated control via intravitreal injection in the mouse eye when entrapped 
in human serum albumin NP (HSA NP)58. In another separate study in 2009, Kim and 
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colleagues evaluated the potential of anionic HSA NP as a promising gene delivery tool for 
RPE cells via the subretinal space59. A category of highly branched nanodimension 
molecules made of central core, interior branches, and exterior surface functional groups, 
known as dendrimers, were also evaluated as potential gene delivery vehicles for in vitro 
and in vivo models. When dendrimer is composed of a high number of surface amine 
functional groups, it condenses negatively charged DNA and protects it from external 
nuclease degradation. Polyethylenimine (PEI) and polyamidoamine (PAMAM) are 
commonly used dendrimers for retinal gene delivery applications due to their “proton 
sponge” mediated endosomal escape attitude. Oligonucleotide polyethylenimin (ODN/PEI) 
complex has been observed to be efficient in transfecting retinal glial cells at 72 hours after 
intravitreal injection in normal rat eyes without any detectable toxicity 60. In another 
attempt, PEI condensed shRNA plasmid DNA to target melanopsin in Balb/c mice, and was 
able to knock down melanopsin in RGC cells at 16 hrs of intravitreal injection, which lasted 
for 2 months61. In 2015, Mastorakos and colleagues showed the combined effect of 
hydroxyl-terminated PAMAM and triamcinolone acetonide (TA) in enhancing transfection 
of dendrimer-gene complex into the most challenging human RPE cells in vitro62. In 2012, 
Sunshine and colleagues synthesized a novel poly (β-amino ester, Fig. 4b), which exhibited 
the expression of reporter GFP gene into the RPE and choroid at post injection of 72 hrs via 
subretinal delivery63. In 2004, Marano and colleagues evaluated for the first time the 
intravitreal delivery of anti-vascular endothelial growth factor (VEGF) oligonucleotide 
(ODN-1) into the rat eyes using the lipophilic amino-acid dendrimer, which significantly 
inhibited laser-induced choroidal neovascularization (CNV) for 4–6 months by 95% in the 
initial stage of CNV development, thereby paving the way for the treatment of angiogenic 
eye disorders 64.
Polycationic compounds (Fig. 4b) are generally limited by their high positive charge and 
significant toxicities. These toxicities are strategically eliminated by encapsulating them in 
conjunction with DNA into the neutrally charged (at physiological pH) biocompatible and 
biodegradable poly (lactic-co-glycolic acid) (PLGA) molecules. PLGA has been widely 
used for drug delivery and approved by both the US Food and Drug Administration (FDA) 
and the European Medicine Agency. In 2010, Zhang and colleagues developed hypoxia-
inducible factor 1α (HIF-1α) shRNA and GFP co-expressed plasmid DNA-loaded PLGA 
NPs (pshHIF-1α NPs) 65. The result showed that the intravitreal injection of these NPs 
reduced the mean area of CNV in the rat laser photocoagulation model without any 
deleterious effects on the retina. Another study by Bejjani and colleagues showed the 
expression of reporter RNFP (red nuclear fluorescence) in RPE cells up to 14 days post 
intraocular injection without any apparent structural damage or toxicity66.
3.3 Polypeptide based vehicles
In the pipeline of developing gene delivery vehicles, polypeptide based systems are 
evaluated as a promising tool for ocular gene delivery. A novel cell penetrating peptide, 
peptide for ocular delivery (POD, CGGG(ARKKAAKA)4), was able to transduce GFP 
protein under the control of CMV promoter, which was expressed into the RPE and 
photoreceptor cells via subretinal injection in C57BL6/J mice67. On intravitreal injection, 
the POD compacted GFP plasmid DNA (POD-GFP) transduced retinal ganglion cells, with 
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limited expression in the inner nuclear layers and lens capsule68. The topical administration 
of POD-GFP expressed GFP protein in the corneal epithelium cells. In 2014, Read and 
colleagues demonstrated that the pegylation of POD peptide was able to increase pCAGLuc 
expression by 215-fold, compared to naked plasmid DNA in the RPE cells by subretinal 
injection in Balb/c mice69. These PEG-POD NPs were also able to protect photoreceptor 
cells by delivering glial cell line-derived neurotrophic factor (GDNF) into the subretinal 
space of the blue light-induced photoreceptor apoptosis adult murine model at the 14th day 
post light treatment70. Based on polylysin and DNA compaction strategy, a novel cationic 
CK30-PEG polymer71 was developed to compact plasmid DNA to form an NP formulation 
(Fig. 5b) that could transfect therapeutic genes to the retinal cells in different mice models. 
The shape of these NPs determines the targets in retinal tissues71. The rod shaped NPs 
transfect the RPE and photoreceptor cells, while ellipsoidal NPs transfect only RPE cells in 
vivo. The major advantage of these NPs is the compaction efficiency of plasmid DNA with 
long molecular range (from 5.3 kb to 20.2Kb), while in all cases the charge of the NPs 
remains neutral, minimizing toxicity72. Subretinal injection of these NPs didn’t leave the 
eye, compared to the AAV mediated ocular gene delivery approach. No apparent toxicity to 
the retinal cells was seen, which makes this NP a promising alternative as a non-viral gene 
delivery vehicle to ocular tissues72. The CK30-PEG compacted GFP reporter gene (driven 
by CMV promoter) was able to highly express to RPE and photoreceptor cells by subretinal 
injection, while intravitreal route of injection exhibited GFP expression mainly in ganglion 
cells along with less amounts in the cornea, trabecular meshwork, and lens. The CK30-PEG 
compacted NPs highly expressed human RPE65 gene driven by VMD2 promoter (RPE cell 
specific) in the RPE cells of RPE65−/− mice model of LCA disease, with long term 
phenotypic rescue (up to 2 years)73, 74. Human photoreceptor cell specific ATP-binding 
cassette transporter gene (ABCA4) gene was expressed by subretinal injection of this 
compacted NP (by CK30-PEG polypeptide), under the control of IRBP promoter 
(photoreceptor cells specific), into the retina of the ABCA4−/−- knockout mice model of 
Stargardt’s disease, with a persistent expression of up to 8 months post injection75. A 
significant amount of retinal degeneration slow (RDS) gene expression with partial rescue of 
photoreceptor cell function was observed when compacted with CK30-PEG and delivered 
into the subretinal space of Rds+/− mice 76. This CK30-PEG has not shown any apparent 
toxicity towards retinal cells, even with a second set of subretinal injection of NPs77, and 
can drive gene expression levels on the same scale and duration as AAV78. These NPs have 
so far been evaluated as a promising ocular gene delivery vehicle, and can be the potential 
tool for ocular gene delivery with some modifications in their chemical structures to target 
primary and secondary retinal neuronal cells.
Conclusion
Despite this promising non-viral delivery vehicle development for ocular tissues, 
achievements primarily have been limited to transfection efficiency into RPE cells, but not 
towards photoreceptor and other neuronal tissues in the eye, which is the origin of major 
retinal disorders. Polypeptide-based vehicles have demonstrated some success, but rational 
chemical modifications of these compounds might develop smart gene delivery cargos as a 
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promising alternative to viral vectors and are very appealing for human ocular gene therapy 
in the near future.
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Diagrams of vertebrate eye (left) and the retina (right).
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A) Photo activation leads to an isomerization of 11-cis retinal molecule to all-trans retinal 
(atRAL) in rhodopsin (conjugation of rod opsin + 11-cis retinal) pigment in outer segment 
disc. The atRAL is now converted to all-trans retinol (atROL) by all-trans retinol 
dehydrogenase (atRDH8) and initiates visual photo transduction processes. B) Simple 
representation of the visual cycle in vertebrate eye. In rod cell, retinal chromophore (11-cis 
retinal) binds to the rod opsin protein and forms GPCR. Absorption of light causes 
activation of this photopigment, and leads to isomerization of the 11-cis retinal to atRAL 
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that is subsequently reduced by atRDH8 to atROL in photoreceptor outer segment. This 
atROL is now transferred to RPE cells via IRBP carrier enzymes, where it is esterified to 
long-chain fatty acids (all-trans retinyl esters) by Lecithin retinol acyltransferase (LRAT). 
All-trans retinyl esters are then enzymatically isomerized and hydrolysed to the 11-cis 
retinol by retinal pigment epithelium-specific 65 kDa (RPE65) isomerohydrolase. This 11-
cis retinol is then finally converted to 11-cis retinal, a universal chromophore for visual 
pigment, by 11-cis retinol dehydrogenase (RDH5), and is consequently shuttled back to 
photoreceptor cells by IRBP to reconstitute rhodopsin pigment in photoreceptor disc, where 
it completes the visual cycle.
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Representative 25 nm icosahedral capsid of AAV virion. The ~5 kb AAV genome is 
packaged within the non-enveloped capsid. A gene of interest is inserted between the ITRs 
under the control of promoter at upstream. ITR: Inverted Terminal Repeat.
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Chemical structures of commonly used non-viral compounds for ocular gene delivery. A) 
Chemical structures of lipid based compounds and B) chemical structures of some 
frequently used polymeric compounds.
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Simple representation of A) lipoplex, where lipid molecules can form bilayer structures and 
are thus able to encapsulate hydrophilic nucleic acids inside the nanoparticle core. The lipid 
coating can be used with different targeting agents. The polyethylene glycol (PEG) can also 
work as a shielding element to protect the nucleic acids from harsh extracellular and 
intracellular nuclease, as well as lysomal environments, and B) polyplex, where morphology 
of the nano-composites depend primarily on the chemical structure and charge of the 
constituent polymer compound (s). The negatively charged nucleic acids and positively 
charged polymers (via electrostatic interactions) constitute the compacted charge-neutral 
DNA nanoparticles. The PEG block shields the nanocompactions and protects it from 
nuclease and other degradative pathways.
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